79 related articles for article (PubMed ID: 9708560)
1. The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis.
Jaarsma D; Guchelaar HJ; Haasdijk E; de Jong JM; Holstege JC
Ann Neurol; 1998 Aug; 44(2):293. PubMed ID: 9708560
[No Abstract] [Full Text] [Related]
2. Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics.
Poduslo JF; Whelan SL; Curran GL; Wengenack TM
Ann Neurol; 2000 Dec; 48(6):943-7. PubMed ID: 11117554
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis.
Reinholz MM; Merkle CM; Poduslo JF
Exp Neurol; 1999 Sep; 159(1):204-16. PubMed ID: 10486188
[TBL] [Abstract][Full Text] [Related]
4. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis.
Liu R; Althaus JS; Ellerbrock BR; Becker DA; Gurney ME
Ann Neurol; 1998 Nov; 44(5):763-70. PubMed ID: 9818932
[TBL] [Abstract][Full Text] [Related]
5. [Acetylcysteine in chronic obstructive pulmonary disease. Secretolytic, antioxidant or placebo?].
Randerath W; Galetke W
Med Monatsschr Pharm; 2003 Nov; 26(11):375-8. PubMed ID: 14652922
[No Abstract] [Full Text] [Related]
6. A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice.
Tanaka K; Okada Y; Kanno T; Otomo A; Yanagisawa Y; Shouguchi-Miyata J; Suga E; Kohiki E; Onoe K; Osuga H; Aoki M; Hadano S; Itoyama Y; Ikeda JE
Exp Neurol; 2008 Jun; 211(2):378-86. PubMed ID: 18423451
[TBL] [Abstract][Full Text] [Related]
7. A case of haemodialysis-associated pseudoporphyria successfully treated with oral N-acetylcysteine.
Cooke NS; McKenna K
Clin Exp Dermatol; 2007 Jan; 32(1):64-6. PubMed ID: 17305908
[TBL] [Abstract][Full Text] [Related]
8. Benefit of tianeptine and morphine in a transgenic model of familial amyotrophic lateral sclerosis.
Chritin M; Savasta M; Besson G
Amyotroph Lateral Scler; 2006 Mar; 7(1):32-7. PubMed ID: 16546757
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model.
Ishigaki A; Aoki M; Nagai M; Warita H; Kato S; Kato M; Nakamura T; Funakoshi H; Itoyama Y
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1037-44. PubMed ID: 17984685
[TBL] [Abstract][Full Text] [Related]
10. Is prostaglandin E(2) a pathogenic factor in amyotrophic lateral sclerosis?
Almer G; Kikuchi H; Teismann P; Przedborski S
Ann Neurol; 2006 Jun; 59(6):980-3. PubMed ID: 16619237
[TBL] [Abstract][Full Text] [Related]
11. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis.
Andreassen OA; Ferrante RJ; Klivenyi P; Klein AM; Shinobu LA; Epstein CJ; Beal MF
Ann Neurol; 2000 Apr; 47(4):447-55. PubMed ID: 10762155
[TBL] [Abstract][Full Text] [Related]
12. Regular exercise is beneficial to a mouse model of amyotrophic lateral sclerosis.
Kirkinezos IG; Hernandez D; Bradley WG; Moraes CT
Ann Neurol; 2003 Jun; 53(6):804-7. PubMed ID: 12783429
[TBL] [Abstract][Full Text] [Related]
13. N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals.
Asevedo E; Cunha GR; Zugman A; Mansur RB; Brietzke E
Rev Neurosci; 2012; 23(4):353-62. PubMed ID: 22944654
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic use of cytoprotective agents in canine and feline hepatobiliary disease.
Webster CR; Cooper J
Vet Clin North Am Small Anim Pract; 2009 May; 39(3):631-52. PubMed ID: 19524797
[TBL] [Abstract][Full Text] [Related]
15. Topical N-acetylcysteine for lamellar ichthyosis.
Redondo P; Bauzá A
Lancet; 1999 Nov; 354(9193):1880. PubMed ID: 10584733
[TBL] [Abstract][Full Text] [Related]
16. [Attempts at treatment of amyotrophic lateral sclerosis].
Domzal T; Ilnicki S
Wiad Lek; 1974 Jun; 27(11):955-7. PubMed ID: 4839886
[No Abstract] [Full Text] [Related]
17. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis.
Louwerse ES; Weverling GJ; Bossuyt PM; Meyjes FE; de Jong JM
Arch Neurol; 1995 Jun; 52(6):559-64. PubMed ID: 7763202
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine prevents increased amphetamine sensitivity in social isolation-reared mice.
Herrmann AP; Benvenutti R; Pilz LK; Elisabetsky E
Schizophr Res; 2014 May; 155(1-3):109-11. PubMed ID: 24725851
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine and vitamin E: an in vitro study of their effect on homogentisic acid polymerization.
Chindamo D; Catenaccio M; Lorenzini S; Selvi E; Molinelli M; Cavallo G; Marcolongo R
Clin Exp Rheumatol; 2003; 21(2):269. PubMed ID: 12747292
[No Abstract] [Full Text] [Related]
20. N-acetylcysteine administration in the critically ill.
Walsh TS; Lee A
Intensive Care Med; 1999 May; 25(5):432-4. PubMed ID: 10401934
[No Abstract] [Full Text] [Related]
[Next] [New Search]
